Regis Management CO LLC held its stake in shares of Glaukos Corporation (NYSE:GKOS) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 10,064 shares of the medical instruments supplier’s stock at the close of the 2nd quarter. Regis Management CO LLC’s holdings in Glaukos Corporation were worth $417,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also modified their holdings of GKOS. Great West Life Assurance Co. Can acquired a new position in shares of Glaukos Corporation in the first quarter valued at approximately $102,000. BNP Paribas Arbitrage SA increased its position in shares of Glaukos Corporation by 740.6% during the second quarter. BNP Paribas Arbitrage SA now owns 3,539 shares of the medical instruments supplier’s stock worth $147,000 after acquiring an additional 3,118 shares in the last quarter. Prudential Financial Inc. bought a new stake in shares of Glaukos Corporation during the first quarter worth $204,000. Los Angeles Capital Management & Equity Research Inc. bought a new stake in shares of Glaukos Corporation during the second quarter worth $262,000. Finally, Caxton Associates LP bought a new stake in shares of Glaukos Corporation during the first quarter worth $272,000.

ILLEGAL ACTIVITY WARNING: “Regis Management CO LLC Has $417,000 Holdings in Glaukos Corporation (GKOS)” was published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.watchlistnews.com/regis-management-co-llc-has-417000-holdings-in-glaukos-corporation-gkos/1605707.html.

In other news, Director Orbimed Advisors Llc sold 580,200 shares of the business’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $38.73, for a total transaction of $22,471,146.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Thomas William Burns sold 1,212 shares of the company’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $41.25, for a total transaction of $49,995.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 980,200 shares of company stock valued at $37,900,263. Corporate insiders own 16.40% of the company’s stock.

GKOS has been the topic of a number of research analyst reports. BidaskClub upgraded shares of Glaukos Corporation from a “hold” rating to a “buy” rating in a report on Saturday, June 24th. Zacks Investment Research raised shares of Glaukos Corporation from a “hold” rating to a “strong-buy” rating and set a $48.00 target price for the company in a research note on Tuesday, July 4th. Roth Capital reduced their target price on shares of Glaukos Corporation from $60.00 to $54.00 and set a “buy” rating for the company in a research note on Thursday, August 3rd. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $56.00 target price on shares of Glaukos Corporation in a report on Thursday, August 3rd. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company’s stock. Glaukos Corporation presently has an average rating of “Buy” and a consensus target price of $49.86.

Glaukos Corporation (GKOS) remained flat at $33.45 during mid-day trading on Tuesday. 131,466 shares of the company traded hands. The company has a 50-day moving average price of $34.23 and a 200 day moving average price of $34.23. Glaukos Corporation has a one year low of $28.72 and a one year high of $52.49. The firm’s market capitalization is $1.15 billion.

About Glaukos Corporation

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS).

Institutional Ownership by Quarter for Glaukos Corporation (NYSE:GKOS)

Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.